Article

Oligomerization Partially Explains the Lowering of A beta 42 in Alzheimer's Disease Cerebrospinal Fluid

Department of Public Health and Caring Sciences/Molecular Geriatrics, Rudbeck Laboratory Uppsala University, Uppsala, Sweden.
Neurodegenerative Diseases (Impact Factor: 3.41). 07/2009; 6(4):139-47. DOI: 10.1159/000225376
Source: PubMed

ABSTRACT The lowering of natively analyzed Abeta42 in cerebrospinal fluid (CSF) is used as a diagnostic tool in Alzheimer's disease (AD). The presence of Abeta oligomers can interfere with such analyses causing underestimation of Abeta levels due to epitope masking. The aim was to investigate if the lowering of CSF Abeta42 seen in AD is caused by oligomerization.
Abeta42 was analyzed under both denaturing and non-denaturing conditions. An Abeta42 oligomer ratio was calculated from these quantifications. The presence of oligomers leads to Abeta42 epitope masking during non-denaturing assays, resulting in a higher ratio.
The Abeta42 oligomer ratio was used for the assessment of oligomerized Abeta in human CSF, after being evaluated in transgenic mouse brain homogenates. AD and mild cognitive impairment (MCI) samples displayed the expected decrease in natively measured Abeta42 compared to healthy controls and frontotemporal dementia, but not when analyzing under denaturing conditions. Accordingly, AD and MCI CSF had a higher Abeta42 oligomer ratio in CSF.
Combining denaturing and non-denaturing quantifications of Abeta42 into an oligomer ratio enables the assessment of Abeta oligomers in biological samples. The increased Abeta42 oligomer ratio for AD and MCI indicates the presence of oligomers in CSF and that the lowering of natively measured Abeta42 is caused by oligomerization.

1 Bookmark
 · 
102 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: According to the predominant theories, soluble amyloid-beta (Aβ) aggregates are the principal neurotoxic agents in Alzheimer’s disease pathology, making them a popular target for the development of therapeutics and diagnostic markers. One of the most commonly used methods for determining the concentration of Aβ is ELISA. However, ELISA was developed for monomeric proteins and may be ill-suited for detecting aggregates. Therefore, we investigated the effect of aggregation on the ELISA measurement and developed a novel chemical pre-treatment method, designed to disaggregate Aβ peptides, to improve the ELISA measurement of the total Aβ concentration.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The DNA assisted solid-phase proximity ligation assay (SP-PLA) provides a unique opportunity to specifically detect prion protein (PrP) aggregates by investigating the collocation of three or more copies of the specific protein. We have developed a SP-PLA that can detect PrP aggregates in brain homogenates from infected hamsters even after a 10 (7)-fold dilution. In contrast, brain homogenate from uninfected animals did not generate a detectable signal at hundred-fold higher concentration. Using either of the two monoclonal anti-PrP antibodies 3F4 and 6H4 we successfully detected low concentrations of aggregated PrP. The presented results provide a proof of concept that this method might be an interesting tool in the development of diagnostic approaches of prion diseases.
    Prion 08/2014; 8(3). DOI:10.4161/pri.32231 · 1.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Affective disorders are associated with an increased occurrence of cognitive deficits and have been linked to cognitive impairment and Alzheimer's disease. The putative molecular mechanisms involved in these associations are however not clear. The aim of this systematic review was to explore clinically founded evidence for amyloid-beta peptides in cerebrospinal fluid and blood as putative biomarkers for affective disorders. Method: Systematic searches in Embase and PubMed databases yielded 23 eligible, observational studies. Results: Despite inconsistencies that were partly ascribed to the application of different assay formats, study results indicate a potentially altered amyloid-beta metabolism in affective disorder. Limitations: Since most studies used a cross-sectional design, causality is difficult to establish. Moreover, methodological rigor of included studies varied and several studies were limited by very low sample numbers. Finally, different assays for amyloid-beta were utilized in the different studies, thus hampering comparisons. Conclusion: To unravel possible risk relations and causalities between affective disorder and Alzheimer's disease and to determine how amyloid-beta concentrations change over time and are associated with cognition as well as affective symptomatology, future research should include prospective, longitudinal studies, implemented in large study populations, where peripheral and central amyloid-p ratios are quantified concomitantly and continuously across various affective phases. Also, to enable inter survey comparisons, the use of standardized pre-analytical/analytical procedures is crucial.
    Journal of Affective Disorders 07/2014; 168C:167-183. DOI:10.1016/j.jad.2014.06.050 · 3.71 Impact Factor